Egypt’s Diabetes market size stood at USD xx billion in 2019 and is projected to reach USD xx billion by 2028, exhibiting a CAGR of xx% during the forecast period.
Diabetes or diabetes mellitus describes a group of metabolic disorders characterized by a high blood sugar level in a person. With diabetes, the body either does not produce enough insulin or the body’s cells do not respond properly to insulin or both.
Egypt’s epidemiological profile, characterized by a high chronic disease burden, will drive prescription medicine expenditure over the coming years. Rapid population growth and a gradually aging population represent potential for pharmaceutical firms to expand, with the emergence of diabetes and other chronic diseases driving the growth of higher value prescription medicines.
Epidemiological studies by the WHO suggest that non-communicable diseases – such as cancer, cardiovascular disease, diabetes, and mental health disorders – are the main causes of morbidity and mortality in Egypt.
According to the latest data from the IDF, there were over 7.8 million cases of diabetes in Egypt in 2016, with diabetes-related deaths reaching a value of 78,184. In 2016, diabetes accounted for 481,031 DALYs in Egypt, which is set to increase by 2030 to 879,976. Such a predicted rise in prevalence is likely to increase the demand for treatment market for diabetes in the country in the forecast period.
Egypt’s Health Ministry has taken several steps for the same and is interested to invest in and promote new developments to tackle the disease burden in the country. These factors will continue to boost the diabetes therapeutics market in Egypt.
The adaptation of unhealthy lifestyle, environmental pollution, and family history with diabetes disease will also boost up the antidiabetic market growth.